<DOC>
	<DOCNO>NCT00093093</DOCNO>
	<brief_summary>The purpose study determine safety effectiveness viramidine ribavirin chronic hepatitis C patient never receive treatment .</brief_summary>
	<brief_title>Study Viramidine Ribavirin Patients With Chronic Hepatitis C Who Are Treatment Naive</brief_title>
	<detailed_description>Compare efficacy safety viramidine 600 mg twice day ( BID ) versus ribavirin 1000/1200 mg/day , drug administer combination pegylated interferon alfa-2a treatment-naive patient chronic hepatitis C ( CHC )</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Treatmentnaive patient compensate chronic hepatitis C. HCV RNA &gt; 2000 copies/mL ( 780 IU/mL ) determine NGI SuperQuant serum HCV RNA quantification , low limit detection 100 copies/mL ( 39 IU/mL ) . Severe neuropsychiatric disorder History clinical manifestation significant metabolic , hematological , pulmonary , ischemic heart disease , significant unstable heart disease , gastrointestinal , neurological , renal , urological , endocrine , ophthalmologic disorder include severe retinopathy , immune mediate disease Pregnant breastfeeding patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Viramidine</keyword>
	<keyword>Ribavirin</keyword>
	<keyword>Valeant</keyword>
	<keyword>Hepatitis C</keyword>
	<keyword>Pegylated interferon alfa-2a</keyword>
</DOC>